This discovery highlights METTL3 as a potential therapeutic target in EBV-associated diseases such as nasopharyngeal carcinoma (NPC), Hodgkin’s lymphoma, and GC, indicating the clinical application prospects of UZH1a. This evidence concerns the gene METTL3 and gastric cancer.